CLINICAL_TRIALS
trial_result
· 2022-11-28
Clinical Trial Update: iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL [Phase 2]
Summary
Phase 2 clinical trial update for iVAC-CLL01, a patient-individualized peptide vaccination after first-line therapy in chronic lymphocytic leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University Hospital Tuebingen | Conditions: Leukemia, Chronic Lymphatic | Phase 2 | Status: COMPLETED